Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid... (serious AEs compared with 7 percent and ...)

Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis

Date:10/27/2008

serious AEs, compared with 7 percent and 5 percent of patients in the golimumab 50 mg and golimumab 100 mg groups, respectively. Serious infections were reported in 3 percent, 3 percent and 1 percent of patients, and injection site reactions (ISR) through week 16 occurred in 3 percent, 4 percent and 11 percent of patients in the placebo, golimumab 50 mg and golimumab 100 mg groups, respectively. The most commonly reported ISR was erythema, a redness of the skin due to inflammation. No serious or severe ISRs were reported, and none led to the discontinuation of patients in the study. Antibodies to golimumab were detected in 4 percent of golimumab-treated patients (50 mg and 100 mg).

About the GO-FORWARD Trial

GO-FORWARD, a Phase 3, multi-center clinical trial included 444 patients with active RA. Adult patients with more than four tender and swollen joints, despite methotrexate therapy, were randomly assigned to receive golimumab (50 or 100 mg) plus methotrexate, golimumab 100 mg plus placebo or placebo plus methotrexate at weeks 0, 4, 8, 12, 16 and 20. Data were assessed at weeks 14 and 24. The co-primary endpoints were percentage of patients achieving ACR 20 response at week 14 and improvement from baseline in HAQ at week 24.

Through week 24, 68 percent of patients in both the combined golimumab plus methotrexate groups and the placebo plus methotrexate group experienced at least one AE. Nine percent of patients in the combined golimumab plus methotrexate groups experienced a serious AE compared with 4 percent of patients receiving placebo plus methotrexate. Three percent of patients in the combined golimumab plus methotrexate groups and 1 percent in the group receiving placebo plus methotrexate experienced serious infections. Rates of ISRs were 5 percent in the combined golimumab plus methotrexate groups and 3 percent in the group receiving placebo plus methotrexate. Two percent of golimumab-treated patients developed antibodies. Four patients
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:

(Date:5/21/2013)... Austin, TX (PRWEB) May 21, 2013 ... and outdoor security solutions, today announced that Genzyme, a ... more units of Door Detective® CL for a multi-use ... already installed in four other Genzyme buildings, this latest ... had with the tailgate detection device improving ...

(Date:5/21/2013)... Many have long discussed the link between mental ... from Clinical Psychiatry.com readdressed the topic of ... suggested using hypnotherapy and other mental health ... that cause acne. , Doctors in the article mentioned ... stress causes changes in the skin that have been ...

(Date:5/21/2013)... May 21, 2013 Synthetic Biologics, Inc. (NYSE MKT: SYN), ... of serious infectious diseases, announced today that Jeffrey ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, ... the Grand Hyatt Hotel. Mr. Riley is scheduled to present ... of Synthetic Biologics, presentation can be accessed by logging onto ...

(Date:5/21/2013)... May 21, 2013 Revolutionary Science, the ... colony counter, announced today that they have expanded their ... , the IncuCount, IntelliCount, InCount and ImpressCount. These ... are especially useful in food microbiology and pharmaceutical manufacturing. ... updated look. A bright white enclosure with jet ...

Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2 Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3 Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2 Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2 Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2

[0] Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security [0] Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions [0] Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference [0] Revolutionary Science Announces New Automatic and Manual Colony Counting Products

... Productivity. , ... Grand Forks, ND (Vocus) December 10, ... individual management practices and fields will become increasingly important to growers, ... Research and Development, will tell agricultural leaders today at the ...

... Dosing Regimen , , ... long-acting therapy (LAT) demonstrated statistically significant symptom control compared ... study presented today (1). Statistical significance was evidenced ... equivalent [eq.a]), when given every 4 weeks with a ...

... Journal Blood for the American Society of Hematology Annual Meeting ... 10 Alfacell Corporation (Nasdaq: ACEL ) today ... in Blood (2008 112: Abstract 4205 & 2008 ... show anti-tumor activity in chronic lymphocytic leukemia (CLL) and acute ...

Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

(Date:5/20/2013)... articles posted online ahead of print 9 ... of geoscience subdisciplines, including minerals exploration, archaeology, planetary ... include Siberia; the Sumatran subduction margin; the Monte ... and the Southeastern U.S. Atlantic Margin. Brief highlights ... tectonics;, 2. The clear fingerprint of ice ages ...

(Date:5/19/2013)... engineered a strain of photosynthetic cyanobacteria to grow without ... today at the 113th General Meeting of the American ... synthetic biology approaches to probe and rewire photoautotrophic (exclusively ... cyanobacterial metabolism for the ability to grow without light ... study. He is part of Shota Atsumi,s lab ...

(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...

[0] New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More [0] Engineered microbes grow in the dark [0] Research examines new methods for managing digestive health

... species previously unknown to science have been discovered on ... environment surrounding hydrothermal vents. The discoveries, made by ... Southampton and British Antarctic Survey, include new species of ... octopus. For the first time, researchers have used ...

... 2011 By manipulating the way bacteria "talk" to ... an unprecedented degree of control over the formation and ... health and industrial applications, particularly to bioreactor technology. ... K. Wood and Associate Professor Arul Jayaraman of the ...

... disguised herself as a man to work as ... French circumnavigation of the globe. The expedition consisted of ... Bougainville and was expected to take three years. A ... vessels; prejudice and custom prevented their participation in science. ...

Cached Biology News:'Lost world' discovered around Antarctic vents 2 Manipulating way bacteria 'talk' could have practical applications, Texas A&M profs say 2 Manipulating way bacteria 'talk' could have practical applications, Texas A&M profs say 3 Jeanne Baret, botanist and first female circumnavigator, finally commemorated in name of new species 2

'Lost world' discovered around Antarctic vents Manipulating way bacteria 'talk' could have practical applications, Texas A&M profs say Jeanne Baret, botanist and first female circumnavigator, finally commemorated in name of new species

...

Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....

Poly A Polymerase catalyzes the addition of AMP to the 3' hydroxyl terminus of RNA. Poly A Polymerase can add poly(C) and poly(U) to RNA but does so with much-reduced efficiency....

Biology Products:

Mae II from Roche Applied Science Xho I from Roche Applied Science Streptavidin, Unconjugated from Roche Applied Science Poly A Polymerase from Invitrogen